Xterna

Using alternative xeno nucleic acids for cell specific targeting

  • Biotech
Therapeutics

Member

Active

Status

2024

Founded

Pre-Seed

Development stage

  • EngBio1
    Accelerate

Xterna is developing cell specific binders that are composed of xeno nucleic acids (XNA). By focusing on cell types that evade protein antigen based targeting approaches, it's able to unlock new cell types for targeted drug delivery.

Founding team

Key contacts